Related Experiment Video

Updated: Jul 4, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Home Insulin Pump Use in Hospitalized Children With Type 1 Diabetes

Jodi Owens1, Joshua Courter2, Christine L Schuler3,4

  • 1Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

JAMA Network Open
|February 7, 2024
PubMed

Insights

Home insulin pumps are safe for hospitalized children with diabetes, showing lower hyperglycemia rates and no diabetic ketoacidosis (DKA) cases. This supports their use in pediatric hospital settings for eligible patients.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Inpatient Care

Background:

  • Limited pediatric data exists on home insulin pump safety during inpatient stays.
  • Understanding safety is crucial for integrating diabetes technology into pediatric hospitals.

Purpose of the Study:

  • To evaluate the safety and accuracy of home insulin pump delivery in hospitalized children managed by patients or caregivers.

Main Methods:

  • Retrospective, observational cohort study of children with insulin-dependent diabetes admitted between 2016-2021.
  • Compared outcomes (hyperglycemia, hypoglycemia, DKA) across home insulin pumps, hospital insulin pumps, and subcutaneous injections.

Main Results:

  • Home insulin pumps showed lower hyperglycemia rates (27.0%) compared to injections (45.2%).
  • Hypoglycemia rates were comparable across all insulin delivery methods.
  • No cases of diabetic ketoacidosis (DKA) occurred in patients using home or hospital insulin pumps.

Conclusions:

  • Home insulin pump use is safe for hospitalized pediatric patients regarding hyperglycemia and hypoglycemia.
  • Data supports the use of home insulin pumps for non-critically ill pediatric patients without active DKA.
Abstract

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.5K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.0K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
197
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
382